A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

Exclusion Criteria

• •You will not be eligible for this study if you:
• •Have received prescription or nonprescription medications within 14 days of study entry, or if you will need to take any of these medications during the study.
• •Have ever received anti-HIV medications.
• •Test positive for hepatitis B.
• •Have received a blood (or red blood cell) transfusion within 3 months prior to study entry.
• •Have severe diarrhea.
• •Have severe heart, liver, kidney, or neurological (brain and spinal cord) disease.
• •Have hemophilia or another blood disorder.
• •Have received certain medications or vaccines within 30 days prior to study entry.
• •Have received chemotherapy or radiation within 16 days prior to study entry, or if you will need either of these during the study.